Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of Your Number one kind of pie - 2Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- 3Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- 4Finding Europe's Head Traveler Objections: An Excursion Through Famous Attractions
- 5OpenAI launches ChatGPT Health to connect medical records, wellness apps
- Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- The Best Design Bloggers for Style Motivation
- Israeli strikes on Beirut, as Hezbollah and Iran attack Israel
- Really focusing on Succulents: Tips and Procedures
- Employers and staff feel effect of fuel price rise
- 7 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- AstraZeneca to acquire Modella AI to speed oncology drug research
- IDF Givati Brigade soldier arrested, charged in suspected Iran espionage
- Untamed life Safe-havens All over the Planet Offering Remarkable Creature Experiences
